Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
CTR20260414 Interferon alpha-2b(Anhui Anke Biotechnology) Respiratory Syncytial Virus Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
CTR20260414 clinical trial report covering Interferon alpha-2b(Anhui Anke Biotechnology), Phase 3, endpoints, sponsor, geography, readout timing and develo
Latest Hotspot
8 min read
JPRN-jRCT2071250151 Etoposide Extensive stage Small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
JPRN-jRCT2071250151 clinical trial report covering Etoposide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ISRCTN39379437 Guselkumab Colonic Diseases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
ISRCTN39379437 clinical trial report covering Guselkumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20261026 Human normal immunoglobulin(Guangdong Shuanglin Biological Pharmaceutical ) Purpura, Thrombocytopenic, Idiopathic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
CTR20261026 clinical trial report covering Human normal immunoglobulin(Guangdong Shuanglin Biological Pharmaceutical ), Phase 3, endpoints, sponsor, geogra
Latest Hotspot
8 min read
NCT07494409 AND-017 Anemia in chronic kidney disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07494409 clinical trial report covering AND-017, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07498634 Recombinant human IL-17A/F humanized antibody(Livzon Pharmaceutical Group) Ankylosing Spondylitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07498634 clinical trial report covering Recombinant human IL-17A/F humanized antibody(Livzon Pharmaceutical Group), Phase 3, endpoints, sponsor, geograp
Latest Hotspot
8 min read
NCT07495852 Travoprost Glaucoma, Open-Angle Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07495852 clinical trial report covering Travoprost, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07496736 Oseltamivir Phosphate Influenza, Human Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07496736 clinical trial report covering Oseltamivir Phosphate, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07496450 mRNA-1018 Influenza, Human Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07496450 clinical trial report covering mRNA-1018, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07497438 Etoposide Lymphohistiocytosis, Hemophagocytic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07497438 clinical trial report covering Etoposide, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07495033 Telitacicept Interstitial lung disease due to connective tissue disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07495033 clinical trial report covering Telitacicept, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
TCTR20260327002 Tranexamic Acid Melanosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
TCTR20260327002 clinical trial report covering Tranexamic Acid, Phase 3, endpoints, sponsor, geography, readout timing and development white space.